OSR Holdings Finalizes Global Licensing Deal for VXM01 with BCM Europe

OSR Holdings has entered into a global exclusive licensing agreement with BCM Europe AG for its VXM01 oral immunotherapy, which is nearing Phase 3 trials. The deal includes potential milestone payments totaling $815 million for OSR Holdings. Additionally, OSR will acquire VXM01's intellectual property rights from Vaximm AG for $30 million, with BCM Europe's equity stake serving as collateral for the milestone obligations.